FKBP5 Gene Expression Predicts Antidepressant Treatment Outcome in Depression
- PMID: 30678080
- PMCID: PMC6387218
- DOI: 10.3390/ijms20030485
FKBP5 Gene Expression Predicts Antidepressant Treatment Outcome in Depression
Abstract
Adverse experiences and chronic stress are well-known risk factors for the development of major depression, and an impaired stress response regulation is frequently observed in acute depression. Impaired glucocorticoid receptor (GR) signalling plays an important role in these alterations, and a restoration of GR signalling appears to be a prerequisite of successful antidepressant treatment. Variants in genes of the stress response regulation contribute to the vulnerability to depression in traumatized subjects. Consistent findings point to an important role of FKBP5, the gene expressing FK506-binding protein 51 (FKBP51), which is a strong inhibitor of the GR, and thus, an important regulator of the stress response. We investigated the role of FKBP5 and FKB51 expression with respect to stress response regulation and antidepressant treatment outcome in depressed patients. This study included 297 inpatients, who participated in the Munich Antidepressant Response Signature (MARS) project and were treated for acute depression. In this open-label study, patients received antidepressant treatment according to the attending doctor's choice. In addition to the FKBP5 genotype, changes in blood FKBP51 expression during antidepressant treatment were analyzed using RT-PCR and ZeptoMARKTM reverse phase protein microarray (RPPM). Stress response regulation was evaluated in a subgroup of patients using the combined dexamethasone (dex)/corticotropin releasing hormone (CRH) test. As expected, increased FKBP51 expression was associated with an impaired stress response regulation at baseline and after six weeks was accompanied by an elevated cortisol response to the combined dex/CRH test. Further, we demonstrated an active involvement of FKBP51 in antidepressant treatment outcome. While patients responding to antidepressant treatment had a pronounced reduction of FKBP5 gene and FKBP51 protein expression, increasing expression levels were observed in nonresponders. This effect was moderated by the genotype of the FKBP5 single nucleotide polymorphism (SNP) rs1360780, with carriers of the minor allele showing the most pronounced association. Our findings demonstrate that FKBP5 and, specifically, its expression product FKBP51 are important modulators of antidepressant treatment outcome, pointing to a new, promising target for future antidepressant drug development.
Keywords: FKBP5; FKBP51; HPA axis; antidepressant treatment; depression; gene expression.
Conflict of interest statement
The authors F.H. and M.U are coinventors of the patent “FKBP51: a novel target for antidepressant therapy” (WO2005054500). All other authors declare no conflict of interest.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6387218/bin/ijms-20-00485-g001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6387218/bin/ijms-20-00485-g002.gif)
Similar articles
-
Effect of the common functional FKBP5 variant (rs1360780) on the hypothalamic-pituitary-adrenal axis and peripheral blood gene expression.Psychoneuroendocrinology. 2014 Apr;42:89-97. doi: 10.1016/j.psyneuen.2014.01.007. Epub 2014 Jan 23. Psychoneuroendocrinology. 2014. PMID: 24636505
-
FK506 binding protein 5 shapes stress responsiveness: modulation of neuroendocrine reactivity and coping behavior.Biol Psychiatry. 2011 Nov 15;70(10):928-36. doi: 10.1016/j.biopsych.2011.07.023. Epub 2011 Sep 10. Biol Psychiatry. 2011. PMID: 21907973
-
Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment.Nat Genet. 2004 Dec;36(12):1319-25. doi: 10.1038/ng1479. Epub 2004 Nov 21. Nat Genet. 2004. PMID: 15565110
-
How to measure glucocorticoid receptor's sensitivity in patients with stress-related psychiatric disorders.Psychoneuroendocrinology. 2018 May;91:235-260. doi: 10.1016/j.psyneuen.2018.01.023. Epub 2018 Feb 2. Psychoneuroendocrinology. 2018. PMID: 29449045 Review.
-
The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders.Psychoneuroendocrinology. 2009 Dec;34 Suppl 1:S186-95. doi: 10.1016/j.psyneuen.2009.05.021. Psychoneuroendocrinology. 2009. PMID: 19560279 Review.
Cited by
-
The association of FKBP5 gene polymorphism with genetic susceptibility to depression and response to antidepressant treatment- a systematic review.BMC Psychiatry. 2024 Apr 12;24(1):274. doi: 10.1186/s12888-024-05717-z. BMC Psychiatry. 2024. PMID: 38609904 Free PMC article.
-
Microbiota-Induced Epigenetic Alterations in Depressive Disorders Are Targets for Nutritional and Probiotic Therapies.Genes (Basel). 2023 Dec 14;14(12):2217. doi: 10.3390/genes14122217. Genes (Basel). 2023. PMID: 38137038 Free PMC article. Review.
-
Antidepressant-like Effect of Oroxylum indicum Seed Extract in Mice Model of Unpredictable Chronic Mild Stress.Nutrients. 2023 Nov 10;15(22):4742. doi: 10.3390/nu15224742. Nutrients. 2023. PMID: 38004136 Free PMC article.
-
The HPA Axis as Target for Depression.Curr Neuropharmacol. 2024;22(5):904-915. doi: 10.2174/1570159X21666230811141557. Curr Neuropharmacol. 2024. PMID: 37581323 Free PMC article.
-
Sex blind: bridging the gap between drug exposure and sex-related gene expression in Danio rerio using next-generation sequencing (NGS) data and a literature review to find the missing links in pharmaceutical and environmental toxicology studies.Front Toxicol. 2023 Jun 16;5:1187302. doi: 10.3389/ftox.2023.1187302. eCollection 2023. Front Toxicol. 2023. PMID: 37398910 Free PMC article.
References
-
- GBD 2017 Disease and Injury Incidence and Prevalence Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789–1858. doi: 10.1016/S0140-6736(18)32279-7. - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous